Photo by danielroe from unsplash
Real‐world data are required to support glucagon‐like peptide‐1 receptor agonist use in type 2 diabetes (T2D). SURE France assessed once‐weekly semaglutide in adults with T2D in real‐world clinical practice. Click to show full abstract
Real‐world data are required to support glucagon‐like peptide‐1 receptor agonist use in type 2 diabetes (T2D). SURE France assessed once‐weekly semaglutide in adults with T2D in real‐world clinical practice.
Keywords:
sure france;
type diabetes;
semaglutide use;
weekly semaglutide
Journal Title: Diabetes
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Diabetes
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!